Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

A systematic protocol for the characterization of Hsp90 modulators.

Matts RL, Brandt GE, Lu Y, Dixit A, Mollapour M, Wang S, Donnelly AC, Neckers L, Verkhivker G, Blagg BS.

Bioorg Med Chem. 2011 Jan 1;19(1):684-92. doi: 10.1016/j.bmc.2010.10.029. Epub 2010 Oct 19.

2.

Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket.

Donnelly A, Blagg BS.

Curr Med Chem. 2008;15(26):2702-17. Review.

3.

Inhibitors of the HSP90 molecular chaperone: current status.

Sharp S, Workman P.

Adv Cancer Res. 2006;95:323-48. Review.

PMID:
16860662
4.

Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators.

Hieronymus H, Lamb J, Ross KN, Peng XP, Clement C, Rodina A, Nieto M, Du J, Stegmaier K, Raj SM, Maloney KN, Clardy J, Hahn WC, Chiosis G, Golub TR.

Cancer Cell. 2006 Oct;10(4):321-30. Epub 2006 Sep 28.

5.

Disruption of the Bcr-Abl/Hsp90 protein complex: a possible mechanism to inhibit Bcr-Abl-positive human leukemic blasts by novobiocin.

Wu LX, Xu JH, Zhang KZ, Lin Q, Huang XW, Wen CX, Chen YZ.

Leukemia. 2008 Jul;22(7):1402-9. doi: 10.1038/leu.2008.89. Epub 2008 Apr 17.

PMID:
18418407
6.

Cucurbitacin D Is a Disruptor of the HSP90 Chaperone Machinery.

Hall JA, Seedarala S, Rice N, Kopel L, Halaweish F, Blagg BS.

J Nat Prod. 2015 Apr 24;78(4):873-9. doi: 10.1021/acs.jnatprod.5b00054. Epub 2015 Mar 10.

PMID:
25756299
7.

Modulation of Hsf1 activity by novobiocin and geldanamycin.

Conde R, Belak ZR, Nair M, O'Carroll RF, Ovsenek N.

Biochem Cell Biol. 2009 Dec;87(6):845-51. doi: 10.1139/o09-049.

PMID:
19935870
8.

Celastrol targets proteostasis and acts synergistically with a heat-shock protein 90 inhibitor to kill human glioblastoma cells.

Boridy S, Le PU, Petrecca K, Maysinger D.

Cell Death Dis. 2014 May 8;5:e1216. doi: 10.1038/cddis.2014.182.

9.

Gambogic acid, a natural product inhibitor of Hsp90.

Davenport J, Manjarrez JR, Peterson L, Krumm B, Blagg BS, Matts RL.

J Nat Prod. 2011 May 27;74(5):1085-92. doi: 10.1021/np200029q. Epub 2011 Apr 12.

10.

Geldanamycin and its derivatives as Hsp90 inhibitors.

Gorska M, Popowska U, Sielicka-Dudzin A, Kuban-Jankowska A, Sawczuk W, Knap N, Cicero G, Wozniak F.

Front Biosci (Landmark Ed). 2012 Jun 1;17:2269-77. Review.

PMID:
22652777
11.

Hsp90 functions in the targeting and outer membrane translocation steps of Tom70-mediated mitochondrial import.

Fan AC, Bhangoo MK, Young JC.

J Biol Chem. 2006 Nov 3;281(44):33313-24. Epub 2006 Sep 12.

12.

Synthesis of Hsp90 dimerization modulators.

Chiosis G, Aguirre J, Nicchitta CV.

Bioorg Med Chem Lett. 2006 Jul 1;16(13):3529-32. Epub 2006 Apr 18.

PMID:
16621545
13.

Novobiocin induces a distinct conformation of Hsp90 and alters Hsp90-cochaperone-client interactions.

Yun BG, Huang W, Leach N, Hartson SD, Matts RL.

Biochemistry. 2004 Jun 29;43(25):8217-29.

PMID:
15209518
14.

Geldanamycin-induced PCNA degradation in isolated Hsp90 complex from cancer cells.

Wang X, Heuvelman DM, Carroll JA, Dufield DR, Masferrer JL.

Cancer Invest. 2010 Jul;28(6):635-41. doi: 10.3109/07357901003630983.

PMID:
20394503
15.
16.

Features of the Streptomyces hygroscopicus HtpG reveal how partial geldanamycin resistance can arise with mutation to the ATP binding pocket of a eukaryotic Hsp90.

Millson SH, Chua CS, Roe SM, Polier S, Solovieva S, Pearl LH, Sim TS, Prodromou C, Piper PW.

FASEB J. 2011 Nov;25(11):3828-37. doi: 10.1096/fj.11-188821. Epub 2011 Jul 21.

PMID:
21778327
17.

Geldanamycin and its anti-cancer activities.

Fukuyo Y, Hunt CR, Horikoshi N.

Cancer Lett. 2010 Apr 1;290(1):24-35. doi: 10.1016/j.canlet.2009.07.010. Epub 2009 Oct 21. Review.

PMID:
19850405
18.

Activation of heat shock factor 1 plays a role in pyrrolidine dithiocarbamate-mediated expression of the co-chaperone BAG3.

Song S, Kole S, Precht P, Pazin MJ, Bernier M.

Int J Biochem Cell Biol. 2010 Nov;42(11):1856-63. doi: 10.1016/j.biocel.2010.07.021. Epub 2010 Aug 6.

19.

NMR backbone assignment of the N-terminal domain of human HSP90.

Jacobs DM, Langer T, Elshorst B, Saxena K, Fiebig KM, Vogtherr M, Schwalbe H.

J Biomol NMR. 2006;36 Suppl 1:52. Epub 2006 Jul 5. No abstract available.

PMID:
16821127
20.

Posttranslational modification and conformational state of heat shock protein 90 differentially affect binding of chemically diverse small molecule inhibitors.

Beebe K, Mollapour M, Scroggins B, Prodromou C, Xu W, Tokita M, Taldone T, Pullen L, Zierer BK, Lee MJ, Trepel J, Buchner J, Bolon D, Chiosis G, Neckers L.

Oncotarget. 2013 Jul;4(7):1065-74.

Supplemental Content

Support Center